IP Library Granted Patent US 7,232,587
Granted Patent B2
US 7,232,587 · App. 10/477,069 · Granted Jun 19, 2007

Method for the passivation of an intraocular lens

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,232,587
App. No.
10/477,069
Granted
Jun 19, 2007
Kind
B2
Abstract

The invention includes a method for the passivation of the surface of an intraocular lens, wherein the surface includes Brönsted sites. The intraocular lens is dipped into a solution of a fluoroalkyl silane having the general formula: R f —(CH 2 ) n —Si—(O—R) 3 . The residue R is selected from the group of H, CH 3 , C 2 H 5 and C 3 H 7 and the fluoroalkyl residue R f is selected from the series CF 3 (CF 2 ) m , with m=3 to 11 and n=0 to 4. The Brönsted sites on the surface are thereby deactivated by formation of Si—Q—bonds.

Claims (11)

1. A method of modifying a surface of an intraocular lens, the surface of which comprises Brönsted sites, the method comprising contacting the surface of the lens with a solution of a fluoroalkyl silane of general formula

R F —(CH 2 ) n —Si—(O—R) 3

wherein R is selected from the group of H, CH 3 , C 2 H 7 , and R F is CF 3 (CF 2 ) m , with m=3 to 11 and n=0 to 4, whereby the fluoroalkyl silane is tethered to the surface by formation of Si—O—bonds at the Brönsted sites on the surface, and the modified surface of the intraocular lens has a fluorine content that is between 2% by weight and 15% by weight, and an oxygen content from 25.1% to 31.3% by weight, as measured by x-ray photoelectron spectroscopy.

2. The method according to claim 1 , wherein the intraocular lens is a silicone lens.

3. The method according to claim 1 , wherein the intraocular lens is a lens made of polymethylmethacrylate (PMMA) or acrylics.

4. The method according to claim 1 , wherein the solution is acidified and comprises between 0.5% by weight and 2% by weight of the fluoroalkyl silane.

5. The method according to claim 1 , wherein R f =CF 3 (CF 2 ) 5 , n=2 and R=CH 2 CH 3 .

6. The method according to claim 1 , wherein the Brönsted sites are formed by OH-groups.

7. The method according to claim 1 , wherein the Brönsted sites are formed by CO 2 -groups.

8. The method according to claim 1 , wherein the solution is acidified and comprises between 0.8% by weight and 1.2% by weight of the fluoroalkyl silane.

9. The method according to claim 1 , wherein the fluorine content is from 3.8% to 11.6% by weight.

Assignments (8)
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
NOTICE OF SUCCESSION OF AGENCY Recorded Jan 9, 2015
From: GOLDMAN SACHS LENDING PARTNERS, LLC
To: BARCLAYS BANK PLC, AS SUCCESSOR AGENT
Reel/Frame 034749/0689 →
SECURITY AGREEMENT Recorded Sep 4, 2013
From: BAUSCH & LOMB INCORPORATED
To: GOLDMAN SACHS LENDING PARTNERS LLC, AS COLLATERAL AGENT
Reel/Frame 031156/0508 →
RELEASE OF SECURITY INTEREST Recorded Aug 13, 2013
From: CITIBANK N.A., AS ADMINISTRATIVE AGENT
To: WP PRISM INC. (N/K/A BAUSCH & LOMB HOLDINGS INC.); BAUSCH & LOMB INCORPORATED; ISTA PHARMACEUTICALS
Reel/Frame 030995/0444 →
SECURITY AGREEMENT Recorded Aug 6, 2012
From: BAUSCH & LOMB INCORPORATED; EYEONICS, INC.
To: CITIBANK N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 028728/0645 →
RELEASE OF SECURITY INTEREST Recorded Aug 5, 2012
From: CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH
To: BAUSCH & LOMB INCORPORATED
Reel/Frame 028726/0142 →
SECURITY AGREEMENT Recorded Mar 26, 2008
From: BAUSCH & LOMB INCORPORATED; WP PRISM INC.; B&L CRL INC.; B&L CRL PARTNERS L.P.; B & L DOMESTIC HOLDINGS CORP.; B&L FINANCIAL HOLDINGS CORP.; B&L SPAF INC.; B&L VPLEX HOLDINGS, INC.; BAUSCH & LOMB CHINA, INC.; BAUSCH & LOMB INTERNATIONAL INC.; BAUSCH & LOMB REALTY CORPORATION; BAUSCH & LOMB SOUTH ASIA, INC.; BAUSCH & LOMB TECHNOLOGY CORPORATION; IOLAB CORPORATION; RHC HOLDINGS, INC.; SIGHT SAVERS, INC.; WILMINGTON MANAGEMENT CORP.; WILMINGTON PARTNERS L.P.; B&L MINORITY DUTCH HOLDINGS LLC
To: CREDIT SUISSE
Reel/Frame 020733/0765 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 12, 2004
From: MENZ, DIRK HENNING; DRESP, JOACHIM; HOERAUF, HANS
To: BAUSCH & LOMB INCORPORATED
Reel/Frame 015197/0333 →